 Frequency clinical implications monoclonal antibody detection tumor-associated antigens serum patients lung cancer panel monoclonal antibodies MAb serum tumor-associated antigens TAA patients lung cancer significant degree patients lung cancer frequency clinical importance serum TAA expression serum initial clinical characteristics Philadelphia VA patients lung cancer period modified semiquantitative ELISA MAb reactivity cohort mean age year SD mean Karnovsky score weight loss present subjects Stage III IV disease panel TAAs cases sensitivity Cl squamous cell adenocarcinoma undifferentiated small cell carcinomas significant differences reactive nonreactive patients terms age stage presentation histologic subtype performance status weight loss risk early death Cox proportional hazard analysis prognostic variables specific serum TAA majority lung cancer patients major histologic subtypes cohort advanced tumors poor prognostic indices